Acura Pharmaceuticals, Inc. ACUR
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | |||
|---|---|---|---|---|---|
| Revenue | -34.15% | -54.63% | -40.97% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -34.15% | -54.63% | -40.97% | ||
| Cost of Revenue | -25.82% | -12.36% | 4.65% | ||
| Gross Profit | -5.50% | -75.39% | -66.05% | ||
| SG&A Expenses | -8.77% | 7.84% | -25.82% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -17.85% | -1.83% | -12.80% | ||
| Operating Income | 6.02% | -171.26% | -178.92% | ||
| Income Before Tax | 61.36% | -225.65% | 56.47% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 61.36% | -225.65% | 56.47% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 61.36% | -225.65% | 56.47% | ||
| EBIT | 6.02% | -171.26% | -178.92% | ||
| EBITDA | 6.06% | -163.95% | -151.00% | ||
| EPS Basic | 83.33% | -194.74% | 56.52% | ||
| Normalized Basic EPS | 66.41% | -193.33% | -457.14% | ||
| EPS Diluted | 83.33% | -205.26% | 50.00% | ||
| Normalized Diluted EPS | 66.41% | -194.92% | -457.14% | ||
| Average Basic Shares Outstanding | 133.67% | 32.77% | 0.60% | ||
| Average Diluted Shares Outstanding | 133.67% | 32.04% | 0.60% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||